Analyst, Alliance Global Partners
Appears in 1 story
Last updated Nov 22, 2026
Covers Sellas
Most adults whose acute myeloid leukemia comes back after treatment have one durable option left: a stem cell transplant. On Nov. 17, 2026, Sellas Life Sciences reported that for patients who could not get one, a maintenance vaccine extended median survival to 24.0 months, against 14.7 months on the best available treatment.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?